ArticleJournal of translational medicine2026
Caveolin-1 drives immunosuppression in esophageal squamous cell carcinoma by enhancing exosome secretion and macrophage M2 polarization via inhibition of MVB autophagic degradation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial architecture of atherosclerotic plaques: coordinating immune responses through mechanotransduction and vesicular trafficking.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundExosomes are pivotal mediators of molecular transfer and intercellular communication, orchestrating interactions between tumor cells and the tumor microenvironment (TME). However, the impact of exosomes derived from esophageal squamous cell carcinoma (ESCC) on macrophages and the mechanisms regulating their secretion remain poorly understood. METHODS IN VITRO: experiments were performed to evaluate the effects of ESCC-derived exosomes on macrophage polarization. Proteomics, bioinformatics analyses, and functional validation were employed to identify key molecules regulating exosome secretion. Stable knockdown cell lines for the candidate molecules, together with co-culture assays, were used to evaluate their effects on exosome secretion and macrophage polarization. Western blotting, transmission electron microscopy, and immunofluorescence were conducted to investigate the underlying mechanisms.
resultsESCC-derived exosomes induced macrophage polarization toward the M2 phenotype in a dose-dependent manner. Functional assays identified caveolin-1 (CAV1) as a critical regulator of exosome secretion. Knockdown of CAV1 markedly reduced exosome release from ESCC cells without affecting multivesicular body (MVB) biogenesis, exosome morphology, or size distribution. CAV1 knockdown had little effect on exosome cargo composition. Moreover, it impaired the capacity of these exosomes to induce M2 polarization in macrophages, consequently enhancing CD8+ T cell proliferation and cytotoxicity. Re-expression of CAV1 restored both exosome secretion and the ability of macrophages to undergo M2 polarization. Mechanistically, CAV1 maintains basal exosome secretion by inhibiting autophagy via sustaining PI3K/AKT/mTOR pathway activity, thereby reducing MVB–autophagic vacuole (AV) fusion and degradation. In vivo, CAV1 knockdown suppressed tumor growth in mouse xenograft models and decreased M2 macrophage infiltration. Analysis of clinical samples further confirmed that CAV1 is highly expressed in ESCC tissues and correlates with increased M2 macrophage infiltration and poor patient prognosis.
conclusionCAV1 regulates exosome secretion in ESCC cells by inhibiting autophagy, mediates macrophage M2 polarization, and promotes the formation of an immunosuppressive TME. These findings highlight the crucial role of CAV1 in tumor immune evasion and suggest it as a potential therapeutic target for ESCC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.